CRISPR, TALEN, and ZFN: Tracking the Competitive Dynamics of Core Technologies and Their Niche Applications in the Gene Editing Market.
The transition of gene editing from laboratory experiments to systemic human therapeutics is fundamentally constrained by one major challenge: effective and safe delivery of the editing components (the guide RNA and the Cas protein) to the target cells *in vivo*. For *ex vivo* therapies, this challenge is manageable, often relying on electroporation or lentiviral vectors. However, to treat...
3843 Views
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek